Prosecution Insights
Last updated: May 29, 2026
Application No. 18/276,527

COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF

Non-Final OA §112
Filed
Aug 09, 2023
Priority
Feb 10, 2021 — provisional 63/147,959 +3 more
Examiner
COLEMAN, BRENDA LIBBY
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Elevatebio Technologies Inc.
OA Round
1 (Non-Final)
75%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
1208 granted / 1617 resolved
+14.7% vs TC avg
Strong +16% interview lift
Without
With
+15.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
34 currently pending
Career history
1656
Total Applications
across all art units

Statute-Specific Performance

§101
2.8%
-37.2% vs TC avg
§103
9.5%
-30.5% vs TC avg
§102
12.3%
-27.7% vs TC avg
§112
49.8%
+9.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1617 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 184-187, 192-194 and 197-207 are pending in this application. Election/Restrictions Applicant’s election without traverse of Group II in the reply filed on February 3, 2026 is acknowledged. Claims 187, 192-194, 197-203 and 207 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on February 3, 2026. Information Disclosure Statement The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION. —The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 186 and 204-206 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The following reasons apply: Claim 186 is vague and indefinite in that it is not known what is meant by “on average about 45”. Claim 204 is vague and indefinite in that it is not known what is meant by “on average about 45”. Claim 205 is vague and indefinite in that it is not known what is meant by “on average about 45”. Claim 206 is vague and indefinite in that it is not known what is meant by “on average about 45”. Claim 206 is a duplicate of claim 186. Allowable Subject Matter Claims 184 and 185 are allowed. None of the prior art of record nor a search in the pertinent art area teaches the compounds of Formula (A) as claimed herein. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRENDA L COLEMAN whose telephone number is (571)272-0665. The examiner can normally be reached Mon-Fri 10-6 (flex). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey H. Murray can be reached on 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRENDA L COLEMAN/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Aug 09, 2023
Application Filed
Apr 07, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12637463
TRICYCLIC KINASE INHIBITORS AND USES THEREOF
4y 1m to grant Granted May 26, 2026
Patent 12637429
NOVEL OXIDIZED LAPPACONITINE DERIVATIVE AND USE THEREOF
3y 8m to grant Granted May 26, 2026
Patent 12636310
THERAPEUTIC AGENT FOR SHORT TEAR BREAKUP TIME-TYPE DRY EYE AND EYE DROPS CONTAINING SAME
3y 0m to grant Granted May 26, 2026
Patent 12630565
DNA-DEPENDENT PROTEIN KINASE INHIBITOR
4y 5m to grant Granted May 19, 2026
Patent 12629359
STRUCTURAL ANALOGUES OF METHYLPHENIDATE AS PARKINSON'S DISEASE-MODIFYING AGENTS
3y 3m to grant Granted May 19, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
75%
Grant Probability
90%
With Interview (+15.7%)
2y 4m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1617 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month